GlassScriptPhysician profile
Jakub Juros
NPI 1104950807
$394,019.22
in general payments reported to CMS, 2019-2025
8 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $18K · 2021: $54K · 2022: $134K · 2023: $79K · 2024: $75K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $24K · Food and Beverage: $8,349 · Consulting Fee: $8,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,325.00 |
| Travel and Lodging | $23,732.15 |
| Food and Beverage | $8,348.95 |
| Consulting Fee | $8,208.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $389,118.68 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $2,319.87 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $1,033.97 | 2019-2023 | Uzedy |
| Neurocrine Biosciences, INC. | $918.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $321.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $195.54 | 2019-2020 | |
| Indivior INC. | $60.03 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jakub Juros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.